281 related articles for article (PubMed ID: 6603478)
21. Tracheal lavage and plasma fibronectin: relationship to respiratory distress syndrome and development of bronchopulmonary dysplasia.
Gerdes JS; Yoder MC; Douglas SD; Paul M; Harris MC; Polin RA
J Pediatr; 1986 Apr; 108(4):601-6. PubMed ID: 3958835
[TBL] [Abstract][Full Text] [Related]
22. Matrix metalloproteinases-2, -8, and -9 and TIMP-2 in tracheal aspirates from preterm infants with respiratory distress.
Cederqvist K; Sorsa T; Tervahartiala T; Maisi P; Reunanen K; Lassus P; Andersson S
Pediatrics; 2001 Sep; 108(3):686-92. PubMed ID: 11533337
[TBL] [Abstract][Full Text] [Related]
23. Cytologic evaluation of pulmonary effluent in neonates with respiratory distress syndrome and bronchopulmonary dysplasia.
Merritt TA; Puccia JM; Stuard ID
Acta Cytol; 1981; 25(6):631-9. PubMed ID: 6947668
[TBL] [Abstract][Full Text] [Related]
24. Eosinophil cationic protein in tracheal aspirates of preterm infants with bronchopulmonary dysplasia.
Raghavender B; Smith JB
J Pediatr; 1997 Jun; 130(6):944-7. PubMed ID: 9202617
[TBL] [Abstract][Full Text] [Related]
25. Soluble vascular endothelial growth factor receptor 1 in tracheal aspirate fluid of preterm neonates at birth may be predictive of bronchopulmonary dysplasia/chronic lung disease.
Hasan J; Beharry KD; Valencia AM; Strauss A; Modanlou HD
Pediatrics; 2009 Jun; 123(6):1541-7. PubMed ID: 19482766
[TBL] [Abstract][Full Text] [Related]
26. Pulmonary endostatin perinatally and in lung injury of the newborn infant.
Janér J; Andersson S; Haglund C; Lassus P
Pediatrics; 2007 Jan; 119(1):e241-6. PubMed ID: 17158946
[TBL] [Abstract][Full Text] [Related]
27. [Superoxide dismutase and catalase activity in tracheobronchial secretions after surfactant treatment of newborn infants with respiratory distress syndrome].
Schröder A; Herting E; Speer CP
Z Geburtshilfe Neonatol; 1999; 203(5):201-6. PubMed ID: 10596413
[TBL] [Abstract][Full Text] [Related]
28. Risk factors for the degradation of lung elastic fibers in the ventilated neonate. Implications for impaired lung development in bronchopulmonary dysplasia.
Bruce MC; Schuyler M; Martin RJ; Starcher BC; Tomashefski JF; Wedig KE
Am Rev Respir Dis; 1992 Jul; 146(1):204-12. PubMed ID: 1626805
[TBL] [Abstract][Full Text] [Related]
29. Pulmonary trypsin-2 in the development of bronchopulmonary dysplasia in preterm infants.
Cederqvist K; Haglund C; Heikkilä P; Sorsa T; Tervahartiala T; Stenman UH; Andersson S
Pediatrics; 2003 Sep; 112(3 Pt 1):570-7. PubMed ID: 12949286
[TBL] [Abstract][Full Text] [Related]
30. Perinatal conditions related to growth restriction and inflammation are associated with an increased risk of bronchopulmonary dysplasia.
Eriksson L; Haglund B; Odlind V; Altman M; Ewald U; Kieler H
Acta Paediatr; 2015 Mar; 104(3):259-63. PubMed ID: 25469645
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of neutrophil elastase by alpha-1-proteinase inhibitor oxidized by activated neutrophils.
Padrines M; Schneider-Pozzer M; Bieth JG
Am Rev Respir Dis; 1989 Mar; 139(3):783-90. PubMed ID: 2784294
[TBL] [Abstract][Full Text] [Related]
32. Effects of dexamethasone on chemotactic activity and inflammatory mediators in tracheobronchial aspirates of preterm infants at risk for chronic lung disease.
Groneck P; Reuss D; Götze-Speer B; Speer CP
J Pediatr; 1993 Jun; 122(6):938-44. PubMed ID: 8388949
[TBL] [Abstract][Full Text] [Related]
33. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops.
Watterberg KL; Demers LM; Scott SM; Murphy S
Pediatrics; 1996 Feb; 97(2):210-5. PubMed ID: 8584379
[TBL] [Abstract][Full Text] [Related]
34. Inhalation or instillation of steroids for the prevention of bronchopulmonary dysplasia.
Bassler D
Neonatology; 2015; 107(4):358-9. PubMed ID: 26044104
[TBL] [Abstract][Full Text] [Related]
35. Alpha-1-proteinase inhibitor in inflammatory states of humans and laboratory animals.
Cochrane CG
Am J Med; 1988 Jun; 84(6A):75-9. PubMed ID: 3260075
[TBL] [Abstract][Full Text] [Related]
36. The proteinase-antiproteinase balance in alpha-1-proteinase inhibitor-deficient lung transplant recipients.
King MB; Campbell EJ; Gray BH; Hertz MI
Am J Respir Crit Care Med; 1994 Apr; 149(4 Pt 1):966-71. PubMed ID: 8143063
[TBL] [Abstract][Full Text] [Related]
37. Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn.
Lassus P; Turanlahti M; Heikkilä P; Andersson LC; Nupponen I; Sarnesto A; Andersson S
Am J Respir Crit Care Med; 2001 Nov; 164(10 Pt 1):1981-7. PubMed ID: 11734455
[TBL] [Abstract][Full Text] [Related]
38. Characterization of sheep alpha-1-proteinase inhibitor. Important differences from the human protein.
Sinha U; Sinha S; Janoff A
Am Rev Respir Dis; 1988 Mar; 137(3):558-63. PubMed ID: 3257851
[TBL] [Abstract][Full Text] [Related]
39. Growth and development of preterm infants with respiratory distress syndrome and bronchopulmonary dysplasia.
Meisels SJ; Plunkett JW; Roloff DW; Pasick PL; Stiefel GS
Pediatrics; 1986 Mar; 77(3):345-52. PubMed ID: 3951915
[TBL] [Abstract][Full Text] [Related]
40. Neonatal plasma concentrations of secretory leucocyte protease inhibitor.
Sveger T; Ohlsson K; Svenningsen N
Acta Paediatr; 1992 Mar; 81(3):270-1. PubMed ID: 1380860
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
